Entellus Medical, Inc. (ENTL) Receives Average Recommendation of “Hold” from Brokerages
Entellus Medical, Inc. (NASDAQ:ENTL) has earned a consensus rating of “Hold” from the ten research firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $21.20.
Several research firms recently weighed in on ENTL. BidaskClub upgraded Entellus Medical from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 14th. Piper Jaffray Companies restated a “buy” rating and set a $21.00 price target on shares of Entellus Medical in a research report on Tuesday, August 22nd. Zacks Investment Research upgraded Entellus Medical from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Finally, ValuEngine upgraded Entellus Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd.
A number of institutional investors have recently added to or reduced their stakes in ENTL. Frontier Capital Management Co. LLC bought a new stake in Entellus Medical in the first quarter worth $6,464,000. William Blair Investment Management LLC boosted its holdings in Entellus Medical by 1,017.0% in the first quarter. William Blair Investment Management LLC now owns 390,334 shares of the medical technology company’s stock worth $5,387,000 after acquiring an additional 355,388 shares in the last quarter. Tekla Capital Management LLC bought a new stake in Entellus Medical in the second quarter worth $5,655,000. Nicholas Company Inc. boosted its holdings in Entellus Medical by 1,052.3% in the second quarter. Nicholas Company Inc. now owns 247,685 shares of the medical technology company’s stock worth $4,101,000 after acquiring an additional 226,190 shares in the last quarter. Finally, Kingdon Capital Management L.L.C. boosted its holdings in Entellus Medical by 79.6% in the first quarter. Kingdon Capital Management L.L.C. now owns 450,371 shares of the medical technology company’s stock worth $6,215,000 after acquiring an additional 199,615 shares in the last quarter. 70.41% of the stock is currently owned by institutional investors and hedge funds.
Entellus Medical (NASDAQ:ENTL) opened at 17.43 on Friday. The firm’s market capitalization is $442.22 million. The stock’s 50 day moving average price is $17.32 and its 200-day moving average price is $15.02. Entellus Medical has a 12 month low of $11.47 and a 12 month high of $22.63.
Entellus Medical (NASDAQ:ENTL) last released its quarterly earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.03. Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. The firm had revenue of $22.10 million for the quarter, compared to the consensus estimate of $21.87 million. During the same quarter in the prior year, the firm earned ($0.27) earnings per share. The company’s revenue for the quarter was up 18.0% compared to the same quarter last year. Equities analysts anticipate that Entellus Medical will post ($1.61) EPS for the current fiscal year.
WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/09/09/entellus-medical-inc-entl-receives-average-recommendation-of-hold-from-brokerages.html.
About Entellus Medical
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.